← Back to Search

Subcutaneous Infusion of Sterile Saline for Healthy Subjects

Phase < 1
Recruiting
Research Sponsored by Janssen Research & Development, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 10 minutes after completion of the saline solution
Awards & highlights

Study Summary

This trial aims to understand how the size of the needle, amount of fluid injected, and speed of injection affect the pain felt by adult volunteers when receiving a saline infusion under the skin.

Who is the study for?
This trial is for healthy adults with a BMI between 18 and 36 who understand English and test negative for COVID-19. It's designed to help understand pain from subcutaneous infusions, which could inform treatments like those used in infertility.Check my eligibility
What is being tested?
The study tests how different needle sizes, fluid volumes, and infusion rates affect pain when injecting sterile saline under the skin of healthy volunteers. This research may improve comfort during such procedures.See study design
What are the potential side effects?
Since only sterile saline is being infused, side effects are expected to be minimal but may include temporary discomfort or pain at the injection site.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 10 minutes after completion of the saline infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 10 minutes after completion of the saline infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Participant's Pain Intensity as Assessed by Verbal Pain Score (VPS)
Participant's Pain Intensity as Assessed by Visual Analog Scale (VAS) Score

Trial Design

1Treatment groups
Experimental Treatment
Group I: Subcutaneous Infusion of Sterile SalineExperimental Treatment1 Intervention
Participants will receive sterile saline subcutaneous infusion administered into abdomen and/or anterior thigh through various sizes of needles at various volume and rate of delivery at Visit 1.

Find a Location

Who is running the clinical trial?

Janssen Research & Development, LLCLead Sponsor
975 Previous Clinical Trials
6,384,341 Total Patients Enrolled
Janssen Research & Development, LLC Clinical TrialStudy DirectorJanssen Research & Development, LLC
745 Previous Clinical Trials
3,959,938 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Which demographic is considered the most suitable for inclusion in this medical study?

"Candidates eligible for this research study must be in good health and aged between 18 to 60 years. The trial has capacity for 32 participants."

Answered by AI

What is the upper limit on the number of participants involved in this medical study?

"Indeed, the details on clinicaltrials.gov reveal that this research study is currently in search of participants. The trial was initially listed on January 12th, 2024 and the latest update occurred on February 2nd, 2024. They aim to enroll a total of 32 subjects at one designated site."

Answered by AI

Are individuals currently able to participate in this research study?

"As per clinicaltrials.gov, this investigation is currently seeking suitable participants. It was initially shared on 1/12/2024 and last modified on 2/2/2024."

Answered by AI

Does this trial enroll participants who are above the age of eighteen?

"Participants in this research must be between 18 and 60 years old. There are currently 74 trials targeting individuals below the age of 18, while there are 401 trials focusing on those above 65 years old."

Answered by AI

Who else is applying?

What site did they apply to?
Thomas Jefferson University
What portion of applicants met pre-screening criteria?
Met criteria
~21 spots leftby Apr 2025